Intervention of Stéphane Delfour at Thai Fact-Checking Network's launch

Stéphane Delfour, AFP Director of the Bangkok bureau, participated Thursday August 24 in the launch of the "Thai Fact-Checking Network", a network of media and organizations committed to the fight against disinformation in Thailand, under the aegis of the Thai Media Fund (TMF), of which AFP is one of the main partners.

AFP journalist wounded in drone attack in east Ukraine

An AFP video journalist was wounded by a drone attack while reporting at a Ukrainian artillery position on Monday, AFP reporters who witnessed the explosion said.


Dylan Collins, a US citizen based in Lebanon but on assignment in Ukraine, sustained multiple shrapnel injuries in the attack in a forested area near Bakhmut.

He was evacuated to a nearby hospital where he was being treated and doctors have said his condition was not life-threatening.

AFP at News Xchange 2023

The 2023 edition of News Xchange, the annual meeting of the international media industry, is currently taking place in Dublin. AFP will take over the emblematic Gravity Bar in Dublin at the Guinness Storehouse on Monday, June 19 from 8 pm for an evening of networking, and will take part in conferences on Tuesday, June 20.

09/17/2026 14:30
Beacon Acquires Haize Labs to Power AI for the Real Economy

Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies. Beacon believes that the fastest way to bring AI to the traditional econo...

08/31/2026 10:00
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and...